Local Nanomedicine and Nano-Enabled Biomaterials After Glioblastoma Resection.

Despite maximal safe resection and chemoradiotherapy, glioblastoma almost invariably recurs near the resection margin. Incomplete tumor removal is only one contributor; infiltrative residual cells, resistant stem-like states, wound-healing responses, local immunosuppression, and limited drug access also promote regrowth. This review examines stand-alone nanocarriers and nano-enabled composites in which nanoscale components are incorporated into hydrogels, scaffolds, or implants at the postoperative cavity-margin interface. Biomaterials lacking a functional nanoscale component are included only as design or procedural comparators. Postoperative resection models are distinguished from intratumoral, unresected orthotopic, ex vivo, and in vitro studies, which provide indirect support. Most evidence of efficacy remains preclinical, whereas human studies mainly address feasibility, safety, pharmacodynamic activity, or workflow precedent. Translation depends on reproducible retention, margin coverage, biologically matched release, brain safety, scalable manufacturing, and neurosurgical compatibility. Local nanomedicine thus remains a conditional postoperative strategy whose clinical value has yet to be established.